US20070248569A1 - Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization - Google Patents

Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization Download PDF

Info

Publication number
US20070248569A1
US20070248569A1 US10/541,492 US54149204A US2007248569A1 US 20070248569 A1 US20070248569 A1 US 20070248569A1 US 54149204 A US54149204 A US 54149204A US 2007248569 A1 US2007248569 A1 US 2007248569A1
Authority
US
United States
Prior art keywords
disease
copolymer
eye
cns
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/541,492
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Sharon Bakalash
Valentin Fulga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to US10/541,492 priority Critical patent/US20070248569A1/en
Assigned to YEDA RESEARCH AND DEVELOPMENT CO. LTD. reassignment YEDA RESEARCH AND DEVELOPMENT CO. LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAKALASH, SHARON, EISENBACH-SCHWARTZ, MICHAL, FULGA, VALENTIN
Publication of US20070248569A1 publication Critical patent/US20070248569A1/en
Priority to US12/437,167 priority patent/US8895501B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention is in the field of Immunology and relates to an eye-drop vaccine comprising a random copolymer, in particular Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, as the active agent, and to a method of therapeutic immunization of a mammal, in particular for neuroprotection in the central nervous system (CNS) or in the peripheral nervous system (PNS) after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity.
  • a random copolymer in particular Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, as the active agent
  • a method of therapeutic immunization of a mammal in particular for neuroprotection in the central nervous system (CNS) or in the peripheral nervous system (PNS) after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity.
  • BSA bovine serum albumin
  • CFA complete Freund's adjuvant
  • CNS central nervous system
  • Cop 1 Copolymer 1, glatiramer acetate
  • FCS fetal calf serum
  • IFA incomplete Freund's adjuvant
  • IOP intraocular pressure
  • MBP myelin basic protein
  • NS nervous system
  • PBS phosphate-buffered saline
  • PNS peripheral nervous system
  • RGC retinal ganglion cells.
  • the nervous system comprises the central and the peripheral nervous system.
  • the peripheral nervous system (CNS) is composed of the brain and spinal cord; the peripheral nervous system (PNS) consists of all of the other neural elements, namely the nerves and ganglia outside of the brain and spinal cord.
  • Damage to the nervous system may result from a traumatic injury, such as penetrating trauma or blunt trauma, or a disease, disorder or condition, including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, diabetic neuropathy, glaucoma, senile dementia, and ischemia.
  • a traumatic injury such as penetrating trauma or blunt trauma
  • a disease, disorder or condition including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, diabetic neuropathy, glaucoma, senile dementia, and ischemia.
  • Neurodegenerative disorders are commonly associated with ongoing neuronal loss in the CNS. Following the loss of neurons caused by primary risk factors, additional (“secondary”) neuronal loss is mediated by self-compounds, such as glutamate, nitric oxide or reactive oxygen species, that exceed their physiological concentrations. These compounds are implicated in various types of neurological disorders and acute CNS injuries. It is interesting to note that the destructive components common to neurodegenerative diseases have also been identified in autoimmune diseases such as multiple sclerosis; in this disease, myelin damage in the CNS is accompanied by subsequent neuronal loss.
  • Glaucoma is a slow-progressing optic neuropathy with a high incidence in the elderly population (approximately 1%). Until recently, it was associated with high intraocular pressure (IOP) and therefore attempts have been focused on slowing down the disease progression by anti-hypertensive drugs. Over the years, it became apparent that glaucoma is a family of diseases and not all are associated with pressure. Moreover, it became clear that even when the disease is associated with pressure, the latter may be reduced to normal and even below normal values and degeneration may continue.
  • IOP intraocular pressure
  • T cells that recognize an antigen of the nervous system promote nerve regeneration or confer neuroprotection, as described for example in PCT Publication No. WO 99/60021. More specifically, T cells reactive to myelin basic protein (MBP) were shown to be neuroprotective in rat models of partially crushed optic nerve (Moalem et al., 1999) and of spinal cord injury (Hauben et al., 2000). Until recently, it had been thought that the immune system excluded immune cells from participating in nervous system repair. It was quite surprising to discover that NS-specific activated T cells could be used to promote nerve regeneration or to protect nervous system tissue from secondary degeneration which may follow damage caused by injury or disease of the CNS or PNS.
  • MBP myelin basic protein
  • the vaccinating antigen should be derived from compounds residing in the site of the lesion.
  • IRBP interphotoreceptor binding protein
  • the use of peptides derived from compounds residing in the myelin associated with the optic nerve led to no benefit to the retinal ganglion cells suffering from IOP elevated insult.
  • Copolymer 1 immunologically cross-reacts with a wide variety of self-reactive T cells. Accordingly, its activity is reminiscent of that of altered peptide ligand, a self-peptide that has been altered and has lost pathogenicity as a result (WO 02/055010; Kipnis and Schwartz, 2002).
  • Copolymer 1 also called Cop 1 or glatiramer acetate
  • Cop 1 is a non-pathogenic synthetic random copolymer composed of the four amino acids: L-Glu, L-Lys, L-Ala, and L-Tyr, with an average molecular fraction of 0.141, 0.338, 0.427, and 0.095, respectively, and an average molecular weight of 4,700-11,000.
  • COPAXONE® a trademark of Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel
  • the brand name for glatiramer acetate is currently an approved drug in many countries for the treatment of multiple sclerosis. It is very well tolerated with only minor adversary reactions.
  • treatment with Cop 1 by ingestion or inhalation is disclosed in U.S. Pat. No. 6,214,791, the sole route of administration of Cop 1 to multiple sclerosis patients is by daily subcutaneous injection.
  • Cop 1 provides a beneficial effect for several additional disorders.
  • Cop 1 suppresses the immune rejection manifested in graft-versus-host disease (GVHD) in case of bone marrow transplantation (Schlegel et al., 1996; U.S. Pat. No. 5,858,964), as well as in graft rejection in case of solid organ transplantation (Aharoni et al., 2001).
  • GVHD graft-versus-host disease
  • Cop 1 and Cop 1-related copolymers and peptides have been disclosed in WO 00/05250 for treating autoimmune diseases.
  • Cop 1 can be used for treatment of CNS disorders. None of these publications discloses immunization by administration of eye-drops containing Cop 1.
  • Poultry vaccines for administration as eye drops comprising a live virus or recombinant DNA coding for immunogenic proteins from infectious agents have been described for prevention of viral diseases in avian animals (Mukibi-Muka et al., 1984; Sharma, 1999; Russell and Mackie, 2001).
  • Copolymer 1 when administered as an eye-drop vaccine, evokes a systemic T cell-dependent immune response needed for neuroprotection in the CNS or PNS, as exemplified by protection of retinal ganglion cells (RGCs) against death induced by acute or chronic intraocular pressure (IOP) elevation.
  • RRCs retinal ganglion cells
  • IOP intraocular pressure
  • the present invention thus relates, in one aspect, to an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide.
  • the present invention relates to the use of an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide, for the manufacture of an eye-drop vaccine.
  • the eye-drop vaccine according to the invention is particularly useful for therapeutic immunization of a mammal, in particular humans, for neuroprotection for treating neuronal degeneration caused by an injury, disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow a primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition, or for protecting CNS and PNS cells from glutamate toxicity.
  • CNS central nervous system
  • PNS peripheral nervous system
  • the present invention provides a method of therapeutic immunization for treating neuronal degeneration caused by an injury, disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow a primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity, which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide, in an amount effective to treat, prevent or inhibit said neuronal degeneration caused by said injury, disease, disorder or condition in the individual.
  • an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide, in an amount effective to treat,
  • the active agent may be administered without any adjuvant, for example in saline or phosphate-buffered saline (PBS), or it may be administered with a soluble adjuvant such as a cytokine, e.g. IL-2, IL-12, GM-CSF or IFN- ⁇ , and the like.
  • a cytokine e.g. IL-2, IL-12, GM-CSF or IFN- ⁇ , and the like.
  • the active agent of the eye-drop vaccine of the invention is Copolymer 1.
  • FIG. 1 shows that Copolymer 1 (Cop-1) has a long-lasting effect in protecting RGCs from IOP-induced death in a chronic model.
  • FIGS. 2A-2B show that immunization with 500 ⁇ g Cop-1 without adjuvant ( 2 A) at the day 7 after the first laser ( 2 B) protects RGCs from IOP-induced RGC death in a chronic model.
  • FIGS. 3A-3B show that the effect of Cop-1 is T cell-dependent. Treatment of elevated IOP in non-thymectomized animals with Cop-1 was more effective than in thymectomized animals ( 3 A) and more effective than the glaucoma drug brimonidine ( 3 B).
  • FIGS. 4A-4B show that Cop-1 applied in eye drops protects from IOP-induced RGC death in a chronic model.
  • Five drops of 1 mg Cop-1 each given at 5-minute intervals were applied immediately ( 4 A) or 7 days ( 4 B) after IOP elevation in a chronic model of IOP elevation. Retinas were excised 3 weeks later.
  • FIGS. 5A-5B show that Cop-1 protects RGCs against acute transient IOP elevation when administered subcutaneously ( 5 A) or as eye drops ( 5 B).
  • Copolymer 1 As used herein, the terms “Copolymer 1”, “Cop 1”, “Cop-1”, and “glatiramer acetate” are each used interchangeably.
  • Cop 1 or a Cop 1-related peptide or polypeptide is intended to include any peptide or polypeptide, including a random copolymer, that cross-reacts functionally with myelin basic protein (MBP) and is able to compete with MBP on the MHC class II in the antigen presentation.
  • MBP myelin basic protein
  • a copolymer for use as active agent in the eye-drop vaccine of the present invention may be a random copolymer comprising a suitable quantity of a positively charged amino acid such as lysine (K) or arginine (R), in combination with a negatively charged amino acid (preferably in a lesser quantity) such as glutamic acid (E) or aspartic acid (D), optionally in combination with a non-charged neutral amino acid such as alanine (A) or glycine (G), serving as a filler, and optionally with an amino acid adapted to confer on the copolymer immunogenic properties, such as an aromatic amino acid like tyrosine (Y) or tryptophan (W).
  • a positively charged amino acid such as lysine (K) or arginine (R)
  • a negatively charged amino acid preferably in a lesser quantity
  • D glutamic acid
  • D aspartic acid
  • D optionally in combination with
  • the copolymers for use in the present invention can be composed of L- or D-amino acids or mixtures thereof.
  • L-amino acids occur in most natural proteins.
  • D-amino acids are commercially available and can be substituted for some or all of the amino acids used to make the copolymers used in the present invention.
  • the present invention contemplates the use of copolymers containing both D- and L-amino acids, as well as copolymers consisting essentially of either L- or D-amino acids.
  • the active agent for use in the present invention comprises at least one random three- or four-amino acid copolymer comprising one amino acid selected from each of the four following groups: (a) lysine (K) and arginine (R); (b) glutamic acid (E) and aspartic acid (D); (c) alanine (A) and glycine (G); and (d) tyrosine (Y) and tryptophan (W).
  • the copolymer comprises a combination of the amino acids tyrosine, glutamic acid, alanine, and lysine, herein designated poly-YEAK, of net overall positive electrical charge, and is most preferably Copolymer 1, of the following molar ratio of the amino acids: about 0.14 glutamic acid, about 0.43 alanine, about 0.10 tyrosine, and about 0.34 lysine. It may be a low molecular weight or high molecular weight copolymer being a polypeptide from about 15 to about 100, preferably from about 40 to about 80, amino acids in length.
  • the copolymer has an average molecular weight of about 2,000-40,000 Da, preferably of about 2,000-13,000 Da, more preferably of about 4,700-13,000 Da, most preferably of about 5,000-9,000 Da, and mostly preferred of about 6,000-8,000 Da.
  • This preferred copolymer, Cop 1 is most preferably in the form of its acetate salt known under the generic name glatiramer acetate. Preferred molecular weight ranges and processes for making a preferred form of Cop 1 are described in U.S. Pat. No. 5,800,808, the entire contents of which are hereby incorporated by reference in their entirety as if fully disclosed herein.
  • the active agent of the eye-drop vaccine of the invention is a Cop 1-related polypeptide that is a random copolymer containing four different amino acids, each from a different one of the groups (a) to (d), but excluding Cop 1.
  • the activity exhibited by Copolymer 1 is expected to remain if one or more of the following substitutions is made in the amino acid composition of the copolymer: aspartic (D) acid for glutamic acid (E), glycine (G) for alanine (A), arginine (R) for lysine (K), and tryptophan (W) for tyrosine (Y).
  • the Cop 1-related polypeptide of the invention may include any of those copolymers disclosed in WO 00/05250, the entire contents of which being hereby incorporated herein by reference as if fully disclosed herein, and other synthetic amino acid copolymers such as the random four-amino acid copolymers described by Fridkis-Hareli et al.
  • copolymers 14-, 35- and 50-mers containing the amino acids phenylalanine, glutamic acid, alanine and lysine (poly-FEAK), or tyrosine, phenylalanine, alanine and lysine (poly-YFAK), and any other similar copolymer to be discovered that can be considered a universal antigen similar to Cop 1.
  • the Cop 1-related polypeptide of the invention is a copolymer containing a combination of three different amino acids each from a different one of three groups of the groups (a) to (d). These copolymers are herein referred to as terpolymers. In a more preferred embodiment, the mole fraction of amino acids of the terpolymers is about what is preferred for Copolymer 1.
  • the terpolymers for use in the present invention contain tyrosine (Y), alanine (A), and lysine (K), hereinafter designated poly-YAK.
  • the average molar fraction of the amino acids in these terpolymers can vary.
  • tyrosine can be present in a mole fraction of about 0.005-0.250;
  • alanine can be present in a mole fraction of about 0.3-0.6;
  • lysine can be present in a mole fraction of about 0.1-0.5, but preferably the molar ratios of tyrosine, alanine and lysine are about 0.10 to about 0.54 to about 0.35.
  • the average molecular weight of poly-YAK is about 2,000-40,000 Da, preferably about 3,000-35,000 Da, more preferably about 5,000-25,000 Da. It is possible to substitute arginine (R) for lysine (K), glycine (G) for alanine (A), and/or tryptophan (W) for tyrosine (Y).
  • the terpolymers for use in the present invention contain tyrosine (Y), glutamic acid (E), and lysine (K), hereinafter designated poly-YEK.
  • the average mole fraction of the amino acids in these terpolymers can vary: glutamic acid can be present in a mole fraction of about 0.005-0.300, tyrosine can be present in a mole fraction of about 0.005-0.250, and lysine can be present in a mole fraction of about 0.3-0.7, but preferably the molar ratios of glutamic acid, tyrosine, and lysine are about 0.26 to about 0.16 to about 0.58.
  • the average molecular weight of poly-YEK is about 2,000-40,000 Da, preferably about 3,000-35,000 Da, more preferably about 5,000-25,000 Da. It is possible to substitute arginine (R) for lysine (K), aspartic acid (D) for glutamic acid (E), and/or tryptophan (W) for tyrosine (Y).
  • the terpolymers for use in the present invention contain lysine (K), glutamic acid (E), and alanine (A), hereinafter designated poly-KEA.
  • K lysine
  • E glutamic acid
  • A alanine
  • the average molar fraction of the amino acids in these polypeptides can also vary.
  • glutamic acid can be present in a mole fraction of about 0.005-0.300
  • lysine can be present in a mole fraction of about 0.2-0.7, but preferably the molar ratios of glutamic acid, alanine and lysine are about 0.15 to about 0.48 to about 0.36.
  • the average molecular weight of YEK is about 2,000-40,000 Da, preferably about 3,000-35,000 Da, more preferably about 5,000-25,000 Da. It is possible to substitute arginine (R) for lysine (K), aspartic acid (D) for glutamic acid (E), and/or glycine (G) for alanine (A).
  • the terpolymers for use in the present invention contain tyrosine (Y), glutamic acid (E), and alanine (A), hereinafter designated poly-YEA.
  • the average molar fraction of the amino acids in these polypeptides can vary.
  • tyrosine can be present in a mole fraction of about 0.005-0.250
  • glutamic acid can be present in a mole fraction of about 0.005-0.300
  • alanine can be present in a mole fraction of about 0.005-0.800, but preferably the molar ratios of glutamic acid, alanine, and tyrosine are about 0.21 to about 0.65 to about 0.14.
  • the average molecular weight of poly-YEA is about 2,000-40,000 Da, preferably about 3,000-35,000 Da, and more preferably about 5,000-25,000 Da. It is possible to substitute tryptophan (W) for tyrosine (Y), aspartic acid (D) for glutamic acid (E), and/or glycine (G) for alanine (A).
  • the terpolymers can be made by any procedure available to one of skill in the art, for example as described in the above-mentioned publications WO 01/52878 and WO 01/93893.
  • polypeptides of fixed sequence can readily be prepared and tested for binding to the peptide-binding groove of the HLA-DR molecules as described in Fridkis-Hareli et al. (1999).
  • Examples of such peptides are those disclosed in WO 005249, the entire contents of which are hereby incorporated by reference as if fully disclosed herein. Thirty-two of the peptides specifically disclosed in said application are reproduced in Table I hereinbelow (SEQ ID NO:1 to NO:32).
  • the present invention relates, in one aspect, to an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide.
  • the present invention relates to the use of an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide for the manufacture of an eye-drop vaccine.
  • the eye-drop vaccine comprises the active agent dissolved in any suitable carrier such as saline or PBS, without any adjuvant.
  • the eye-drop vaccine comprises the active agent together with a suitable soluble adjuvant such as a soluble cytokine as exemplified, but not limited to, the cytokines IL-2, IL-12, GM-CSF or IFN- ⁇ .
  • a suitable soluble adjuvant such as a soluble cytokine as exemplified, but not limited to, the cytokines IL-2, IL-12, GM-CSF or IFN- ⁇ .
  • the present invention further relates to a method of therapeutic immunization for neuroprotection which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide, in an amount effective to afford neuroprotection to said individual.
  • the invention provides a method of therapeutic immunization for treating neuronal degeneration caused by an injury in the CNS or PNS, which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide, in an amount effective to treat the neuronal degeneration caused by the injury in said individual.
  • the invention provides a method of therapeutic immunization for preventing or inhibiting neuronal secondary degeneration which may otherwise follow a primary injury in the CNS, which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide, in an amount effective for preventing or inhibiting the neuronal degeneration which may follow a primary injury in the CNS of said individual.
  • the invention provides a method of therapeutic immunization for promoting nerve regeneration in the CNS or in the PNS after an injury, which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide, in an amount effective for promoting nerve regeneration in the CNS or in the PNS of said individual after the injury.
  • Any injury in the CNS or PNS can be treated according to the invention such as, but not limited to, spinal cord injury, blunt trauma, penetrating trauma, brain coup or bicoup, hemorrhagic stroke, and ischemic stroke.
  • the invention relates to a method of therapeutic immunization for treating neuronal degeneration caused by a disease, disorder or condition in the CNS or PNS, which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide, in an amount effective to treat the neuronal degeneration caused by the disease, disorder or condition in the CNS or PNS of said individual.
  • an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide
  • the invention relates to a method of therapeutic immunization for promoting nerve regeneration in the CNS or in the PNS after a disease, disorder or condition, which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide, in an amount effective to promote nerve regeneration in the CNS or in the PNS needed following a disease, disorder or condition of the CNS or PNS in said individual.
  • the invention relates to a method of therapeutic immunization for protecting CNS and PNS cells from glutamate toxicity, which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide, and a Copolymer 1-related polypeptide, in an amount effective to protect CNS or PNS cells in said individual from glutamate toxicity.
  • a senile dementia including Alzheimer's disease, a Parkinsonian syndrome including Parkinson's disease, facial nerve (Bell's) palsy, Huntington's chorea, a motor neuron disease including amyotrophic lateral sclerosis, a prion disease including Creutzfeldt-Jakob disease, Alper's disease, Batten disease, Cockayne syndrome, Lewy body disease, status epilepticus, carpal tunnel syndrome, intervertebral disc herniation, vitamin deficiency such as vitamin B deficiency, epilepsy, amnesia, anxiety, hyperalgesia, psychosis, seizures, oxidative stress, opiate tolerance and dependence, an autoimmune disease such as multiple sclerosis (MS), or a peripheral neuropathy associated with a disease such as amyloid polyneuropathy, diabetic neuropathy, uremic neuropathy, porphyric polyneuropathy, hypoglycemia, S
  • MS multiple sclerosis
  • peripheral neuropathy associated with a disease such as amyloid
  • Copolymer 1 emulsified in adjuvant was found to be protective for RGCs against elevated IOP in a chronic model of elevated IOP.
  • Cop-1 is strong enough and thus can evoke an intensive immune response that can protect effectively against consequences of IOP in both acute and chronic models of IOP.
  • Cop-1 when administered in a regimen used for chronic MS disease, i.e. daily repeated injection, wipes out the benefit of a single injection, substantiating the contention that the requirements for autoimmune disease and for neurodegenerative disease are different (Schwartz and Kipnis. 2002; Kipnis and Schwartz, 2002). While the former needs suppression and the latter needs immune activation, the two may be met if one takes an approach of immunomodulation.
  • Cop-1 is protective in glaucoma.
  • the evoked T cells home to the eye in which they encounter microglia that can present the same self-antigen residing in the eye with which they can cross-react.
  • the activated T cells are the source of cytokine and neurotrophic factors needed for the protection.
  • Our in vitro studies have suggested that activated T cells can upregulate cluster of genes in microglia that can cope with stress and also genes that are associated with their buffering activity.
  • NMDA antagonists NO synthetase inhibitors.
  • NO synthetase inhibitors As glaucoma like any other neurodegenerative disease is not a single compound disease it is suggestive that in order to get a global protection one has to combine several drugs.
  • the advantage of the vaccination according to the invention is in the fact that it simulates the body's own way of getting rid of stress and it invokes activity of the immune cells that is site-specific, but not insult-specific, and thus can protect from a wide range of threats.
  • Cop 1 eye drops a single treatment with Cop 1 eye drops was found as an effective therapy in protecting RGCs against IOP-induced RGC loss in acute and chronic glaucoma rat models.
  • Cop 1 confers neuroprotection systemically when administered as eye drops.
  • the eye-drop vaccine comprising Copolymer 1, a Copolymer 1-related peptide or a Copolymer 1-related polypeptide is used to treat glaucoma, namely to arrest progression of glaucoma, a neurodegenerative disease of the optic nerve.
  • IOP intraocular pressure
  • a single vaccination with Cop 1, given in eye drops (or subcutaneously, for comparison) is sufficient to rescue RGCs from IOP-induced loss.
  • the preferred copolymer for use as the active agent of the invention is Cop 1, most preferably in the form of its acetate salt known under the generic name glatiramer acetate.
  • the dosage of Cop 1 to be administered will be determined by the physician according to the age of the patient and stage of the disease and may be chosen from a range of 0.1 to 1,000 mg, preferably from a range of 10-80 mg, more preferably 20-60 mg, although any other suitable dosage is encompassed by the invention.
  • the administration may be made daily in one or more doses, preferably from one to three daily doses in a total of 0.1 to 1,000 mg, preferably within a range of 10-80 mg, more preferably 20-60 mg, or in alternate days, but any other suitable dosage is envisaged by the invention according to the condition of the patient.
  • the dosage of Cop 1 is as indicated above in a periodical frequency, e.g. at least once a week, to at least once a month or at least once every 2 or 3 months, or less frequently, but any other suitable interval between the immunizations is envisaged by the invention according to the condition of the patient.
  • IOP chronically high intraocular pressure
  • a slit lamp emitting blue-green argon laser irradiation (Haag-Streit, Köniz, Switzerland) was used to treat the right eye of the anesthetized rat with 80 to 120 applications directed toward three of the four episcleral veins and toward 270° of the limbal plexus.
  • the laser beam was applied with a power of 1 W for 0.2 seconds, producing a spot size of 100 ⁇ m at the episcleral veins and 50 ⁇ m at the limbal plexus.
  • the spot size was 100 ⁇ m in all applications. Irradiation was directed toward all four episcleral veins and 360° of the limbal plexus (Schori et al., 2001).
  • Cop-1 in PBS was given at different concentrations and at different time points after the primary insult subcutaneously. Topical administration of Cop-1 was done after immersing the substance in PBS at a concentration of 20 mg/ml. Since each drop was of 50 ⁇ l, we administered 1 drop every 5 minutes for a total of 5 drops in 25 minutes.
  • Cop-1 Vaccination Protects RGCs From IOP-Induced Death When Given Without Vehicle
  • Cop 1 emulsified in an adjuvant protects against IOP-induced RGC death.
  • Animals were subjected to unilateral elevation of IOP and immunized on the day of laser treatment (to induce IOP elevation). Rats were subjected to chronic elevation of IOP on the day of the first laser irradiation. Animals were divided into 4 groups: two groups received Cop-1 emulsified in CFA and two groups received PBS in CFA. From one group of Cop-1-treated animals retinas were excised 3 weeks later and the second group received Cop-1 2, 6 and 9 weeks latter. From this group, retinas were excised 12 weeks after the first laser irradiation.
  • Cop-1 is a high molecular weight compound with multiple epitopes, we considered the possibility that it might be immunogenic even without adjuvant.
  • rats were subjected to IOP elevation and received subcutaneous injection of different dosages of adjuvant-free Cop-1 at various dosages (100, 250, 500 and 1000 ⁇ g) on the first day of laser treatment; control animals received PBS.
  • the results are depicted in FIG. 2A and show that the optimal effect could be achieved with 500 ⁇ g of Cop-1 injected subcutaneously to the rat; higher dosage or lower were less effective.
  • the group treated with 500 ⁇ g showed the highest effect: 26.6 ⁇ 10% of RGC death as compared to 44 ⁇ 6% of RGC death in the group treated with 100 ⁇ g and 50.5 ⁇ 8% of RGC death in the group treated with 250 ⁇ g. In all groups 4-6 animals were included.
  • Cop-1 is indeed immune-mediated and does not act as a local drug.
  • Cop-1 therapy is T cell-mediated and we have shown above that a single injection without adjuvant is sufficient to display protection, we explored now the possibility of using Cop-1 as eye drops without adjuvant. Assuming that approximately 10% of the eye drops get into the blood, we applied drops equivalent to 5 mg Cop-1 (ten-fold the optimal 500 ⁇ g found to be active when given subcutaneously).
  • the Cop-1 eye drops were given either immediately ( FIG. 4A ) or 7 days ( FIG. 4B ) after IOP elevation in a chronic model.
  • the Cop-1 protection with the eye drops was as effective as when given subcutaneously, when assessed 3 weeks after pressure elevation (p ⁇ 10 ⁇ 5 ; 103 RGCs vs. 150 RGCs).
  • Fridkis-Hareli M Santambrogio L, Stern J N, Fugger L, Brosnan C, Strominger J L. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. J Clin Invest 109(12):1635-1643 (2002)
  • tissue-specific self-pathogen is the protective self-antigen: The case of uveitis. J Immunol. 169, 5971-5977 (2002)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
US10/541,492 2003-01-07 2004-01-06 Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization Abandoned US20070248569A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/541,492 US20070248569A1 (en) 2003-01-07 2004-01-06 Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization
US12/437,167 US8895501B2 (en) 2003-01-07 2009-05-07 Eye-drop vaccine containing copolymer 1 for therapeutic immunization

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43831003P 2003-01-07 2003-01-07
PCT/IL2004/000006 WO2004060265A2 (en) 2003-01-07 2004-01-06 Eye-drop vaccine containing copolymer 1 for therapeutic immunization
US10/541,492 US20070248569A1 (en) 2003-01-07 2004-01-06 Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/000006 A-371-Of-International WO2004060265A2 (en) 2003-01-07 2004-01-06 Eye-drop vaccine containing copolymer 1 for therapeutic immunization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/437,167 Division US8895501B2 (en) 2003-01-07 2009-05-07 Eye-drop vaccine containing copolymer 1 for therapeutic immunization

Publications (1)

Publication Number Publication Date
US20070248569A1 true US20070248569A1 (en) 2007-10-25

Family

ID=32713312

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/541,492 Abandoned US20070248569A1 (en) 2003-01-07 2004-01-06 Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization
US12/437,167 Expired - Fee Related US8895501B2 (en) 2003-01-07 2009-05-07 Eye-drop vaccine containing copolymer 1 for therapeutic immunization

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/437,167 Expired - Fee Related US8895501B2 (en) 2003-01-07 2009-05-07 Eye-drop vaccine containing copolymer 1 for therapeutic immunization

Country Status (11)

Country Link
US (2) US20070248569A1 (https=)
EP (1) EP1583506B1 (https=)
JP (1) JP5291878B2 (https=)
CN (2) CN102580069B (https=)
AT (1) ATE548045T1 (https=)
AU (1) AU2004203772B2 (https=)
CA (1) CA2512735C (https=)
ES (1) ES2386435T3 (https=)
IL (1) IL169552A (https=)
MX (1) MXPA05007329A (https=)
WO (1) WO2004060265A2 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100135953A1 (en) * 2006-06-28 2010-06-03 Yeda Research And Development Co., Ltd Method of treatment of age-related macular degeneration
US20110230413A1 (en) * 2010-03-16 2011-09-22 Suhayl Dhib-Jalbut Predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US20110305668A1 (en) * 2008-08-15 2011-12-15 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Methods for using interferon gamma to absorb fluid from the subretinal space
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
US9200114B2 (en) 2011-04-21 2015-12-01 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
AU2010319559A1 (en) 2009-11-10 2012-05-31 Allegro Pharmaceuticals, Inc. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
WO2015038891A2 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional peptide analogs of pedf
CN106491614A (zh) * 2016-12-06 2017-03-15 郑州郑先医药科技有限公司 一种用于治疗脊髓损伤的西药组合及用途
WO2018136669A2 (en) * 2017-01-19 2018-07-26 Allegro Phamaceuticals, Inc. Therapeutic and neuroprotective peptides
KR102874471B1 (ko) 2018-03-05 2025-10-31 매사추세츠 아이 앤드 이어 인퍼머리 콜로니 자극 인자의 표적화에 의한 녹내장 및 시신경병증 치료법
US20230181458A1 (en) * 2020-04-30 2023-06-15 Jeffrey E. Koziol Micro dosing of viral vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6844314B2 (en) * 2000-01-20 2005-01-18 Yeda Research Development Co., Ltd. Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927679T2 (de) 1988-10-27 1997-06-26 Univ Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
ZA93216B (en) 1992-01-17 1993-08-18 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant.
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6153182A (en) * 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
EP1054880A1 (en) * 1998-02-13 2000-11-29 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
US6616925B1 (en) * 1998-04-02 2003-09-09 I.D.M. Immuno-Designed Molecules Combined preparation for the treatment of neoplasic diseases or of infectious diseases
JP2003517452A (ja) * 1999-02-05 2003-05-27 アルク−アベル・アー／エス 新規粘膜デリバリーシステム
PL364983A1 (en) * 1999-08-24 2004-12-27 Teva Pharmaceutical Industries, Ltd. A vaccine composition and method of using the same
DK1294390T3 (da) 2000-06-07 2006-04-03 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
IL160105A0 (en) * 2001-12-06 2004-06-20 Yeda Res & Dev Vaccine for treatment of motor neurone diseases
CA2540701A1 (en) * 2003-09-29 2005-04-07 Chugai Seiyaku Kabushiki Kaisha Proteins expressed in nk cells
JP4501562B2 (ja) 2004-07-09 2010-07-14 旭硝子株式会社 積層膜付き基材およびその製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6844314B2 (en) * 2000-01-20 2005-01-18 Yeda Research Development Co., Ltd. Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US7407936B2 (en) * 2000-01-20 2008-08-05 Yeda Research And Development Co. Ltd. Use of copolymer 1 and related peptides and polypeptides and T cells treated herewith for neuroprotective glaucoma therapy

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089509B2 (en) * 2006-06-28 2015-07-28 Yeda Research And Development Co., Ltd. Method of treatment of age-related macular degeneration
US20100135953A1 (en) * 2006-06-28 2010-06-03 Yeda Research And Development Co., Ltd Method of treatment of age-related macular degeneration
US20110305668A1 (en) * 2008-08-15 2011-12-15 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Methods for using interferon gamma to absorb fluid from the subretinal space
US8697046B2 (en) * 2008-08-15 2014-04-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of administering interferon gamma to absorb fluid from the subretinal space
US9486502B2 (en) 2008-08-15 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of administering interferon gamma to absorb fluid from the subretinal space
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE50301E1 (en) 2010-01-04 2025-02-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US9687522B2 (en) 2010-03-16 2017-06-27 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US20110230413A1 (en) * 2010-03-16 2011-09-22 Suhayl Dhib-Jalbut Predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US9625473B2 (en) 2010-10-11 2017-04-18 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
US9063153B2 (en) 2010-10-11 2015-06-23 Teva Pharmaceuticals Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US9200114B2 (en) 2011-04-21 2015-12-01 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US9499868B2 (en) 2011-10-10 2016-11-22 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
US12343371B2 (en) 2017-03-26 2025-07-01 Mapi Pharma Ltd. Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate

Also Published As

Publication number Publication date
JP5291878B2 (ja) 2013-09-18
IL169552A (en) 2012-05-31
CN102580069A (zh) 2012-07-18
HK1084034A1 (en) 2006-07-21
ATE548045T1 (de) 2012-03-15
US8895501B2 (en) 2014-11-25
CN102580069B (zh) 2015-09-30
WO2004060265A2 (en) 2004-07-22
AU2004203772B2 (en) 2009-07-16
AU2004203772A1 (en) 2004-07-22
EP1583506B1 (en) 2012-03-07
CA2512735C (en) 2016-03-08
WO2004060265A3 (en) 2005-09-22
JP2006515870A (ja) 2006-06-08
US20090214470A1 (en) 2009-08-27
EP1583506A2 (en) 2005-10-12
MXPA05007329A (es) 2005-09-30
CA2512735A1 (en) 2004-07-22
CN1758922A (zh) 2006-04-12
EP1583506A4 (en) 2009-01-07
ES2386435T3 (es) 2012-08-21

Similar Documents

Publication Publication Date Title
US8895501B2 (en) Eye-drop vaccine containing copolymer 1 for therapeutic immunization
JP4328050B2 (ja) 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
CN100438906C (zh) 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途
Bakalash et al. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure
AU2002345323B2 (en) Use of poly-Glu, Tyr for neuroprotective therapy
AU2007264682B2 (en) Method of treatment of age-related macular degeneration
EP2301569A2 (en) Vaccine and method for treatment of neurodegenerative diseases
Schwartz Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders
US20030017136A1 (en) Pharmaceutical compositions comprising vitamin B12 and interferon-beta for treating multiple sclerosis
HK1084034B (en) Eye-drop vaccine containing copolymer 1 for therapeutic immunization
US20050220803A1 (en) Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
WO2004060266A2 (en) Eye-drop vaccine containing copolymer poly-ye for therapeutic immunization
Schwartz Immune-Based Cell Therapy for Acute and Chronic Neurodegeneratlve Disorders
IL159535A (en) USE OF POLY-Glu50, Tyr50 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR NEUROPROTECTION THERAPY
HK1064951B (en) Use of poly-glu, tyr for neuroprotection therapy of the cns or pns
HK1058892B (en) The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith in protecting cns cells from glutamate toxicity

Legal Events

Date Code Title Description
AS Assignment

Owner name: YEDA RESEARCH AND DEVELOPMENT CO. LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAKALASH, SHARON;FULGA, VALENTIN;EISENBACH-SCHWARTZ, MICHAL;REEL/FRAME:017698/0680;SIGNING DATES FROM 20050714 TO 20050720

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION